4Tech Inc., a developer of solutions for transcatheter treatment of Tricuspid Regurgitation (TR), secured $29m in series B financing.
The round was led by Valiance and RMM, with participation from existing and new investors NeoMed Management, and a group of business angels within the Aortic and Mitral Structural Heart Disease.
The funds will be used to gain European market entry for the 4Tech TriCinch™ system for TTVR.
Led by Carine Schorochoff, Co-Founder and CEO, 4Tech has developed the TriCinch™ system, a ranscatheter device designed to allow clinicians to repair a diseased tricuspid heart valve in a reproducible interventional procedure.
The company is incorporated in Delaware, USA, with operations in Galway, Ireland as 4Tech Cardio Ltd.
FinSMEs
09/03/2016